Cardiovascular Considerations for Medications

Introduction to Phosphodiesterase Type-5 Inhibitors

Sildenafil is a selective phosphodiesterase type-5 inhibitor that causes vasodilation through the NO/cGMP pathway, according to the European Heart Journal 1, 2
Common side effects of sildenafil include headache, flushing, epistaxis, and dyspepsia, which are generally mild to moderate and transient, as noted by the European Heart Journal 2

Anabolic steroids like oxandrolone can affect cardiovascular health, potentially causing hypertension, altered lipid profiles, and increased risk of cardiovascular events, which should be considered when combining with sildenafil 3
The Princeton Consensus recommendations suggest integrating multiple aspects of cardiometabolic health when assessing risk for sexual activity and PDE5 inhibitor use, such as sildenafil 3
Patients should be evaluated for cardiovascular risk factors before combining oxandrolone and sildenafil, as part of a risk assessment approach 3

Sildenafil is absolutely contraindicated in patients taking nitrates in any form and in those taking riociguat due to potentially life-threatening hypotension, as recommended by the European Respiratory Society and European Heart Association 4, 2
Medications that inhibit CYP3A4, such as ketoconazole, itraconazole, ritonavir, erythromycin, and fluconazole, can significantly increase sildenafil levels, requiring dose adjustment, as reported by the European Respiratory Society and European Heart Association 4, 2, 1, 5
Bosentan reduces sildenafil levels by approximately 50% while sildenafil increases bosentan levels by 50%, as noted by the European Respiratory Society 4
Cyclosporine and cimetidine require caution when co-administered with sildenafil, as advised by the European Respiratory Society 4
The interaction between fluconazole and sildenafil can increase the risk of adverse effects due to elevated sildenafil levels, and a dose reduction of approximately 60% is recommended when used concurrently, as noted by the European Heart Journal 1, 2

Blood pressure should be monitored regularly when initiating the combination of oxandrolone and sildenafil, as part of ongoing monitoring recommendations
Patients should be educated about potential signs of adverse cardiovascular effects when using oxandrolone and sildenafil concurrently 3
Patients taking fluconazole and sildenafil concurrently should be closely monitored for sildenafil-related adverse effects, particularly hypotension and cardiovascular symptoms, and informed about potential signs of sildenafil toxicity 2
Patients with severe hepatic or renal impairment may require dose adjustment, although specific guidance is not provided by the European Respiratory Society 4